Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive
research, current management of amyotrophic lateral sclerosis remains suboptimal from …

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive
and fatal neurodegenerative disease that leads to a loss of muscle control due to nerve cells …

Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Importance Clinical trial activity in amyotrophic lateral sclerosis (ALS) is dramatically
increasing; as a result, trial modifications have been introduced to improve efficiency …

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive and incurable
neurodegenerative disease. While pharmacotherapy options remain limited, the Food and …

Edaravone, the first known free radical scavenger, has demonstrated cellular protective
properties in animals and humans. Owing to its antioxidant activity, edaravone modulates …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with motor neuron loss
as a defining feature. Despite significant effort, therapeutic breakthroughs have been …

Abstract Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that leads to
progressive disability and motor impairment. Existing therapies provide modest …

Thoughtful clinical trial design is critical for efficient therapeutic development, particularly in
the field of amyotrophic lateral sclerosis (ALS), where trials often aim to detect modest …

Phenyl-3-methyl-5-pyrazolone is a reagent, known as PMP, used to derivatize
monosaccharides for the study of polysaccharides composition and structure, and for the …